JP2005521639A5 - - Google Patents

Download PDF

Info

Publication number
JP2005521639A5
JP2005521639A5 JP2003543536A JP2003543536A JP2005521639A5 JP 2005521639 A5 JP2005521639 A5 JP 2005521639A5 JP 2003543536 A JP2003543536 A JP 2003543536A JP 2003543536 A JP2003543536 A JP 2003543536A JP 2005521639 A5 JP2005521639 A5 JP 2005521639A5
Authority
JP
Japan
Prior art keywords
cyanomethyl
trans
cyclohexanecarboxamide
methyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003543536A
Other languages
English (en)
Japanese (ja)
Other versions
JP4343690B2 (ja
JP2005521639A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/036352 external-priority patent/WO2003041649A2/en
Publication of JP2005521639A publication Critical patent/JP2005521639A/ja
Publication of JP2005521639A5 publication Critical patent/JP2005521639A5/ja
Application granted granted Critical
Publication of JP4343690B2 publication Critical patent/JP4343690B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003543536A 2001-11-13 2002-11-13 プロテアーゼ阻害薬としてのシアノアルキルアミノ誘導体 Expired - Fee Related JP4343690B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35131601P 2001-11-13 2001-11-13
PCT/US2002/036352 WO2003041649A2 (en) 2001-11-13 2002-11-13 Cyanoalkylamino derivatives as protease inhibitors

Publications (3)

Publication Number Publication Date
JP2005521639A JP2005521639A (ja) 2005-07-21
JP2005521639A5 true JP2005521639A5 (https=) 2009-03-26
JP4343690B2 JP4343690B2 (ja) 2009-10-14

Family

ID=23380408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003543536A Expired - Fee Related JP4343690B2 (ja) 2001-11-13 2002-11-13 プロテアーゼ阻害薬としてのシアノアルキルアミノ誘導体

Country Status (8)

Country Link
US (1) US7371747B2 (https=)
EP (1) EP1446115B1 (https=)
JP (1) JP4343690B2 (https=)
AT (1) ATE387197T1 (https=)
AU (1) AU2002352663B2 (https=)
CA (1) CA2466115A1 (https=)
DE (1) DE60225316T2 (https=)
WO (1) WO2003041649A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759428B2 (en) 2001-12-04 2004-07-06 Roche Palo Alto Llc Indole nitriles
HUP0402344A2 (hu) 2001-12-04 2005-02-28 F. Hoffmann-La Roche Ag Helyettesített 2-amino-cikloalkán-karboxamidok, felhasználásuk cisztein-proteáz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CN100430052C (zh) * 2002-03-05 2008-11-05 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
MXPA04011472A (es) 2002-05-22 2005-02-14 Amgen Inc Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor.
AR041191A1 (es) 2002-08-08 2005-05-04 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos
EP1575576A2 (en) 2002-09-24 2005-09-21 Novartis AG Organic compounds
EP1761485A1 (en) * 2003-06-04 2007-03-14 Schering AG Amidino compounds as cysteine protease inhibitors
JP4690319B2 (ja) 2003-06-30 2011-06-01 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
CA2532948A1 (en) * 2003-07-21 2005-02-17 Novartis Ag Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
CN1839114A (zh) * 2003-08-21 2006-09-27 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
PT1663958E (pt) * 2003-09-18 2015-06-01 Virobay Inc Compostos contendo haloalquilo como inibidores de protease de cisteína
AU2005212438A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
AR055283A1 (es) * 2004-11-23 2007-08-15 Merck Frosst Canada Ltd Inhibidores de cisteinproteasa de catepsina
EP1819667B1 (en) * 2004-12-02 2012-10-17 ViroBay, Inc. Sulfonamide compounds as cysteine protease inhibitors
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7488848B2 (en) * 2005-03-21 2009-02-10 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
US7893093B2 (en) * 2005-03-22 2011-02-22 Virobay, Inc. Sulfonyl containing compounds as cysteine protease inhibitors
CN103172568A (zh) * 2005-07-06 2013-06-26 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
EP2079683B1 (en) * 2006-10-04 2015-01-21 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US7893112B2 (en) * 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2240491B1 (en) 2008-01-09 2015-07-15 Amura Therapeutics Limited TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
JP2011525189A (ja) 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 hdac 저해제 화합물
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
US8324417B2 (en) * 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
US9617259B2 (en) * 2013-03-14 2017-04-11 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
CN103275034B (zh) * 2013-04-16 2015-07-08 南京工业大学 一类小分子cathepsin D抑制剂的制备方法
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313847A3 (en) * 1987-10-01 1989-11-29 G.D. Searle & Co. Non-peptidyl alpha-succinamidoacyl aminodiols as anti-hypertensive agents
DE60021254T2 (de) 1999-03-15 2006-04-20 AXYS Pharmaceuticals, Inc., South San Francisco N-cyanomethylamide als protease inhibitoren

Similar Documents

Publication Publication Date Title
JP2005521639A5 (https=)
US6455502B1 (en) Compounds and compositions as protease inhibitors
US10214477B2 (en) (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
JP2010504342A5 (https=)
US7897623B2 (en) ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
HRP20140105T1 (hr) Novi inhibitori seh i njihova upotreba
US7371747B2 (en) Cyanoalkylamino derivatives as protease inhibitors
RU2419624C2 (ru) Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2
HRP20130220T1 (hr) Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih
AR048306A1 (es) Derivados de acidos carboxilicos aromaticos con capacidad moduladora de los niveles de insulina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos metabolicos que responden a la regulacion de gpr40
RU2012129737A (ru) Замещенные бензамидные производные
RU2007119427A (ru) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе
JP2022519301A5 (https=)
RU2012145298A (ru) Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний
US20040014796A1 (en) Novel compounds and compositions as cathepsin S inhititors
HRP20140970T1 (hr) Spoj azolkarboksamida ili njegova sol
CA2482346A1 (en) Substituted phenylacetamides and their use as glucokinase activators
AR042342A1 (es) Derivados de pirazina que presentan efecto inhibidor selectivo sobre gsk3, proceso de preparacion y formulaciones farmaceuticas que los contienen
CA2504207A1 (en) New amide compounds having mch-antagonistic activity and medicaments comprising these compounds
NZ332478A (en) Use of collagenase-3 selective inhibitors for treating joint diseases
JP2024518792A5 (https=)
JP2015502335A5 (https=)
CA2647819A1 (en) Phenylcyclohexyl derivatives as dgat1 inhibitors
JP2008519761A5 (https=)
CA2433520A1 (en) Novel compounds and compositions as cathepsin inhibitors